Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
Company seeks to further the understanding and treatment of GI disease
ATLANTA, Jan. 9, 2014 EndoChoice® today announced the launch of its Investigator-Initiated Study Program (IIS) to further build clinical evidence for the Fuse™ Endoscopy System. The Fuse IIS Program will provide research grants to interested researchers to support independent, investigator-initiated research that is scientifically compelling and consistent with advancing the understanding of the clinical significance of the Fuse technology.
Unlike traditional forward viewing endoscopes that only have a single imager, the Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract. Clinicians are switching to the Fuse system in an effort to improve the quality of their procedures. A recent tandem clinical study concluded that this exceptionally wide field of view enables many clinical benefits such as lower adenoma miss rates, improved surveillance rates, and increased adenoma detection rates (ADR).
"EndoChoice is committed to supporting independent, investigator-initiated studies that further the understanding and treatment of GI diseases with the Fuse Endoscopy System," said Mark Gilreath, Founder and CEO at EndoChoice. "We are confident, and the recent tandem study has shown, that the benefits of seeing more anatomy with the Fuse system will empower physicians to provide higher levels of care. We believe data generated from investigator-initiated research will continue to confirm the benefits of this technology."
Potential investigators interested in participating are invited to submit a proposal via the website: http://www.endochoice.com/Fuse-IIS
Based in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com
EndoChoice® and Fuse™ are trademarks of EndoChoice, Inc
For more information, press only:
Doug Ladd, Chief Marketing Officer
513-608-6873 or Doug.Ladd@endochoice.com
©2012 PR Newswire. All Rights Reserved.